Torthaí cuardaigh - Barbara J. Gitlitz
- 1 - 20 toradh as 24 á dtaispeáint
- Téigh chuig an gcéad leathanach eile
-
1
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma de réir Suresh S. Ramalingam, Chandra P. Belani, Christopher Ruel, Paul Frankel, Barbara J. Gitlitz, Marianna Koczywas, Igor Espinoza‐Delgado, David R. Gandara
Foilsithe / Cruthaithe 2009Artigo -
2
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma de réir Barbara J. Gitlitz, Carole Baker, Yvonne Chapman, Heather Allen, Linda D. Bosserman, Ravi Patel, J. Sanchez, Richard Shapiro, Robert A. Figlin
Foilsithe / Cruthaithe 2003Artigo -
3
Renal cell carcinoma with retroperitoneal lymph nodes de réir Allan J. Pantuck, Amnon Zisman, Frederich Dorey, Debby H. Chao, Ken‐ryu Han, Jonathan W. Said, Barbara J. Gitlitz, Arie S. Belldegrun, Robert A. Figlin
Foilsithe / Cruthaithe 2003Artigo -
4
Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial de réir Barbara J. Gitlitz, James Moon, Bonnie S. Glisson, Hans Reimers, Martin J. Bury, Justin D. Floyd, Thomas K. Schulz, P. Kothai Sundaram, Christopher Ho, David R. Gandara
Foilsithe / Cruthaithe 2010Artigo -
5
Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib de réir Linda Mileshkin, Rodney J. Hicks, Brett Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine
Foilsithe / Cruthaithe 2011Artigo -
6
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib de réir Primo N. Lara, Jeff Longmate, Philip C. Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara J. Gitlitz, Tianhong Li, M. Koczywas, Karen L. Reckamp, David R. Gandara
Foilsithe / Cruthaithe 2015Artigo -
7
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer de réir Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel, Athanassios Argiris, Marianna Koczywas, Barbara J. Gitlitz, Sachdev Thomas, Igor Espinoza‐Delgado, Everett E. Vokes, David R. Gandara, Chandra P. Belani
Foilsithe / Cruthaithe 2009Artigo -
8
Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium de réir Nicholas Campbell, Rangesh Kunnavakkam, Natasha B. Leighl, Mark Vincent, David R. Gandara, Marianna Koczywas, Barbara J. Gitlitz, Edem Agamah, Sachdev Thomas, Walter M. Stadler, Everett E. Vokes, Hedy L. Kindler
Foilsithe / Cruthaithe 2012Artigo -
9
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure t... de réir Sai‐Hong Ignatius Ou, Thomas K. Lee, Lauren Young, Maria Y. Fernandez-Rocha, Dean Pavlick, Alexa B. Schrock, Viola W. Zhu, Jeffrey C. Milliken, Siraj M. Ali, Barbara J. Gitlitz
Foilsithe / Cruthaithe 2017Artigo -
10
IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy de réir Solange Peters, A.W. Kim, Benjamin Solomon, David R. Gandara, Rafał Dziadziuszko, Alessandro Brunelli, Marina Chiara Garassino, Martin Reck, L. Wang, Ikpesu TO, Si Sun, Barbara J. Gitlitz, A. Sandler, Naiyer A. Rizvi
Foilsithe / Cruthaithe 2019Artigo -
11
Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small... de réir Janessa Laskin, Garth Nicholas, Christopher Lee, Barbara J. Gitlitz, Mark Vincent, Yvon Cormier, Joe Stephenson, Yee Ung, Rachel E. Sanborn, Bryn Pressnail, F. Warren Nugent, John Nemunaitis, Martin Gleave, Nevin Murray, Desirée Hao
Foilsithe / Cruthaithe 2011Artigo -
12
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer de réir Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch, Vincent A. Miller, Kwok‐Kin Wong, Barbara J. Gitlitz, Keith D. Eaton, Charles Zacharchuk, Amy Freyman, Christine Powell, Revathi Ananthakrishnan, Susan Quinn, Jean‐Charles Soria
Foilsithe / Cruthaithe 2010Artigo -
13
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epider... de réir Karen L. Reckamp, Paul Frankel, Nora Ruel, Philip C. Mack, Barbara J. Gitlitz, Tianhong Li, Marianna Koczywas, Shirish M. Gadgeel, Mihaela Cristea, Chandra P. Belani, Edward M. Newman, David R. Gandara, Primo N. Lara
Foilsithe / Cruthaithe 2019Artigo -
14
Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors de réir Adil Daud, Smitha Krishnamurthi, Mansoor N. Saleh, Barbara J. Gitlitz, Mitesh J. Borad, Philip J. Gold, Elena G. Chiorean, Gregory M. Springett, Richat Abbas, Shefali Agarwal, Nathalie Bardy‐Bouxin, Poe‐Hirr Hsyu, Eric Leip, Kathleen Turnbull, Charles Zacharchuk, Wells A. Messersmith
Foilsithe / Cruthaithe 2011Artigo -
15
HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib de réir S.-H.I. Ou, Alexa B. Schrock, Eduard V. Bocharov, Samuel J. Klempner, Charbel Haddad, Gary Steinecker, Melissa L. Johnson, Barbara J. Gitlitz, Jon Chung, Paulo Vidal Campregher, J.S. Ross, P. Stephens, V.A. Miller, James Suh, Siraj M. Ali, Vamsidhar Velcheti
Foilsithe / Cruthaithe 2016Artigo -
16
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib de réir Sai‐Hong Ignatius Ou, Alexa B. Schrock, Eduard V. Bocharov, Samuel J. Klempner, Carolina Kawamura Haddad, Gary Steinecker, Melissa L. Johnson, Barbara J. Gitlitz, Jon Chung, Paulo Vidal Campregher, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, James Suh, Siraj M. Ali, Vamsidhar Velcheti
Foilsithe / Cruthaithe 2016Artigo -
17
2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSC... de réir C. Zhou, Meghna Das Thakur, Manoj Srivastava, Wen Zou, Hongjie Xu, M. Ballinger, Enriqueta Felip, Heather A. Wakelee, Nasser K. Altorki, Martin Reck, Rüediger Liersch, Anna Kryzhanivska, M. Harada, Hiroshi Tanaka, John Hamm, Steve McCune, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, Silvia Novello
Foilsithe / Cruthaithe 2021Artigo -
18
Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study de réir Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana Leal, Saiama N. Waqar, Barbara J. Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenant, Liping Du, Joel W. Neal, Jon P. Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, Allison Holzhausen, Christine M. Lovly, Heather A. Wakelee
Foilsithe / Cruthaithe 2018Artigo -
19
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer de réir C.A. Carter, Arun Rajan, Corrine Keen, Éva Szabó, Sean Khozin, Adam D. Thomas, Christina Brzezniak, Udayan Guha, L. Austin Doyle, Seth M. Steinberg, Liqiang Xi, Mark Raffeld, Yusuke Tomita, Min-Jung Lee, S. Lee, Jane B. Trepel, Karen L. Reckamp, S. Koehler, Barbara J. Gitlitz, Ravi Salgia, David Gandara, Everett E. Vokes, Giuseppe Giaccone
Foilsithe / Cruthaithe 2016Artigo -
20
<i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer de réir Kartik Konduri, Jean‐Nicolas Gallant, Young Kwang Chae, Francis J. Giles, Barbara J. Gitlitz, Kyle Gowen, Eiki Ichihara, Taofeek K. Owonikoko, Vijay Peddareddigari, Suresh S. Ramalingam, Satyanarayan K. Reddy, Beth Eaby‐Sandy, Tiziana Vavalà, Andrew R. Whiteley, Heidi Chen, Yingjun Yan, Jonathan H. Sheehan, Jens Meiler, Deborah Morosini, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali, Christine M. Lovly
Foilsithe / Cruthaithe 2016Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Medicine
Oncology
Internal medicine
Cancer
Lung cancer
Chemotherapy
Gastroenterology
Cancer research
Epidermal growth factor receptor
Biology
Surgery
Clinical endpoint
Erlotinib
Gene
Immunotherapy
Regimen
Gefitinib
Phases of clinical research
Receptor
Tyrosine-kinase inhibitor
Adverse effect
Atezolizumab
Breast cancer
Carboplatin
Cisplatin
Colorectal cancer
Genetics
Pathology
Progressive disease
Randomized controlled trial